{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:35Z","timestamp":1787019635022,"version":"build-2736575974"},"reference-count":72,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has recently been added to the armamentarium in the battle against B-cell acute lymphoblastic leukemia (B-ALL). In this review, we discuss the trials that led to US Food and Drug Administration approval of CAR T-cell therapies in patients with B-ALL. We evaluate the evolving role of allogeneic hematopoietic stem cell transplant in the CAR T-cell era and discuss lessons learned from the first steps with CAR T-cell therapy in ALL. Upcoming innovations in CAR technology, including combined and alternative targets and off-the-shelf allogeneic CAR T-cell strategies are presented. Finally, we envision the role that CAR T cells could take in the management of adult patients with B-ALL in the near future.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009462","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T10:44:18Z","timestamp":1678704258000},"page":"3350-3360","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel"},{"name":"3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9404","authenticated-orcid":false,"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"4Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"5Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"5Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"3","key":"2023072113300219000_bib1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2023072113300219000_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Gokbuget","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2023072113300219000_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023072113300219000_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023072113300219000_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1080\/10428194.2020.1751839","article-title":"Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed\/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database","volume":"61","author":"Jabbour","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2023072113300219000_bib6","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2023072113300219000_bib7","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.33469","article-title":"Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"127","author":"Jabbour","year":"2021","journal-title":"Cancer"},{"issue":"6382","key":"2023072113300219000_bib8","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"8","key":"2023072113300219000_bib9","first-page":"715","article-title":"Targeted therapy in acute lymphoblastic leukaemia","volume":"11","author":"Salvaris","year":"2021","journal-title":"J\u00a0Pers Med"},{"issue":"5","key":"2023072113300219000_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023072113300219000_bib11","first-page":"S112","author":"Rives","year":"2022"},{"issue":"21","key":"2023072113300219000_bib12","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2023072113300219000_bib13","article-title":"Real-world outcomes for pediatric and young adult patients with relapsed or refractory (r\/r) b-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the center for international blood and marrow transplant research (CIBMTR) registry","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023072113300219000_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023072113300219000_bib15","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023072113300219000_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","article-title":"Three-year results from phase 1 of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"108","author":"Wayne","year":"2023","journal-title":"Haematologica"},{"issue":"27","key":"2023072113300219000_bib17","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023072113300219000_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023072113300219000_bib19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"10299","key":"2023072113300219000_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"2023072113300219000_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7010","article-title":"Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) in ZUMA-3","volume":"40","author":"Shah","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2023072113300219000_bib22","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate cd19 chimeric antigen receptor-t therapy in adults with relapsed or refractory b-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023072113300219000_bib23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2023072113300219000_bib60","article-title":"Tandem CD19\/CD22 dual targets CAR T-cells bridging hematopoietic stem cells transplantation acquires robust remission for relapsed and refractory B acute lymphoblastic leukemia patients","volume":"138","author":"Cui","year":"2021","journal-title":"Blood"},{"issue":"224","key":"2023072113300219000_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"2023072113300219000_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023072113300219000_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2023072113300219000_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"24","key":"2023072113300219000_bib28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023072113300219000_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"2023072113300219000_bib30","article-title":"A\u00a0phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023072113300219000_bib31","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1182\/blood-2022-157448","article-title":"Primary analysis of a pilot study of prophylactic anakinra to mitigate car t cell-associated toxicity in patients with relapsed or refractory large b-cell lymphoma","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023072113300219000_bib32","first-page":"1","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"2023072113300219000_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor t-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023072113300219000_bib34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072113300219000_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"2023072113300219000_bib36","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072113300219000_bib37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/ relapsed B-cell acute lymphomalastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"2023072113300219000_bib38","article-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, Center for","author":"Auletta","year":"2021","journal-title":"International Blood & Marrow Transplant Research"},{"issue":"8","key":"2023072113300219000_bib39","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2023072113300219000_bib40","doi-asserted-by":"crossref","first-page":"255.e1","DOI":"10.1016\/j.jtct.2020.12.020","article-title":"Allogeneic hematopoietic cell transplantation for relapsed and refractory philadelphia negative b cell all in the era of novel salvage therapies","volume":"27","author":"Aldoss","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2023072113300219000_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2023072113300219000_bib42","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2023072113300219000_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"2023072113300219000_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2023072113300219000_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"2023072113300219000_bib46","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2023072113300219000_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR T cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"20","key":"2023072113300219000_bib48","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2023072113300219000_bib49","first-page":"1","article-title":"Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2023072113300219000_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-011-0900-1","article-title":"Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese pediatric leukemia\/lymphoma study group","volume":"94","author":"Iwamoto","year":"2011","journal-title":"Int J Hematol"},{"issue":"12","key":"2023072113300219000_bib51","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2023072113300219000_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-021-00465-9","article-title":"A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL","volume":"11","author":"Tan","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023072113300219000_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023072113300219000_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"2023072113300219000_bib55","article-title":"CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory ALL","volume":"138","author":"Frey","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023072113300219000_bib56","article-title":"SCRI-CAR19x22v2\u00a0T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023072113300219000_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"2023072113300219000_bib58","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2023072113300219000_bib59","article-title":"Tandem CD19\/CD22 dual targets CART cells therapy acquires superior cr rate than CD19 CAR-T cells: a case controlled study","volume":"136","author":"Cui","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2023072113300219000_bib61","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2023072113300219000_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"issue":"586","key":"2023072113300219000_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"2023072113300219000_bib64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0355-5","article-title":"Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19\/CD22 CAR T cell treatment","volume":"17","author":"Guo","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"2023072113300219000_bib65","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bjh.14899","article-title":"Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia","volume":"182","author":"Turazzi","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"2023072113300219000_bib66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2023072113300219000_bib67","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.3390\/ijms20235942","article-title":"CSPG4-specific CAR T cells for high-risk childhood B cell precursor leukemia","volume":"20","author":"Harrer","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10266","key":"2023072113300219000_bib68","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2023072113300219000_bib69","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"2023072113300219000_bib70","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic `off-the-shelf' CD19-directed CAR-T for patients with relapsed\/refractory (R\/R) CD19+B-ALL","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023072113300219000_bib71","article-title":"Preliminary results from the flu\/cy\/alemtuzumab arm of the phase I BALLI-01 Trial of UCART22, an antiCD22 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD22+B-cell acute lymphoblastic leukemia (B-ALL)","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023072113300219000_bib72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3350\/2065364\/blooda_adv-2022-009462-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3350\/2065364\/blooda_adv-2022-009462-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T09:31:21Z","timestamp":1689931881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3350\/494868\/Chimeric-antigen-receptor-T-cell-therapy-for-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":72,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009462","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}